1
|
Jung E, Jeong SW, Lee Y, Jeon C, Shin H, Song N, Lee Y, Lee D. Self-deliverable and self-immolative prodrug nanoassemblies as tumor targeted nanomedicine with triple cooperative anticancer actions. Biomaterials 2022; 287:121681. [PMID: 35917709 DOI: 10.1016/j.biomaterials.2022.121681] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Revised: 07/11/2022] [Accepted: 07/14/2022] [Indexed: 11/26/2022]
Abstract
Stimulus-responsive self-assembling prodrug-based nanomedicine has emerged as a novel paradigm in controlled drug delivery. All-trans retinoic acid (RA), one of vitamin A metabolites, induces apoptotic cancer cell death, but its clinical applications are limited by weak anticancer efficacy. To fully maximize the therapeutic potential of RA, we exploited the unique chemistry of arylboronic acid which undergoes hydrogen peroxide (H2O2)-triggered degradation to release quinone methide (QM) that alkylates glutathione (GSH) to disrupt redox homeostasis and is also converted into hydroxybenzyl alcohol (HBA) to suppress the expression of vascular endothelial growth factor (VEGF). Here, we report that boronated retinoic acid prodrug (RABA) can be formulated into self-deliverable nanoassemblies which release both RA and QM in a H2O2-triggered self-immolative manner to exert cooperative anticancer activities. RABA nanoassemblies exert anticancer effects by inducing reactive oxygen species (ROS)-mediated apoptosis, eliciting immunogenic cell death (ICD) and suppressing angiogenic VEGF expression. The excellent anticancer efficacy of RABA nanoassemblies can be explained by benefits of self-assembling prodrug-based drug self-delivery and cooperative anticancer actions. The design strategy of RABA would provide a new insight into the rational design of self-deliverable and self-immolative boronated prodrug nanoassemblies for targeted cancer therapy.
Collapse
Affiliation(s)
- Eunkyeong Jung
- Department of Bionanotechnology and Bioconvergence Engineering, Jeonbuk National University, Baekjedaero 567, Jeonju, Jeonbuk, 54896, Republic of Korea
| | - Seung Won Jeong
- Department of Bionanotechnology and Bioconvergence Engineering, Jeonbuk National University, Baekjedaero 567, Jeonju, Jeonbuk, 54896, Republic of Korea
| | - Yeongjong Lee
- Department of Bionanotechnology and Bioconvergence Engineering, Jeonbuk National University, Baekjedaero 567, Jeonju, Jeonbuk, 54896, Republic of Korea
| | - Chanhee Jeon
- Department of Bionanotechnology and Bioconvergence Engineering, Jeonbuk National University, Baekjedaero 567, Jeonju, Jeonbuk, 54896, Republic of Korea
| | - Hyunbin Shin
- Department of Bionanotechnology and Bioconvergence Engineering, Jeonbuk National University, Baekjedaero 567, Jeonju, Jeonbuk, 54896, Republic of Korea
| | - Nanhee Song
- Department of Bionanotechnology and Bioconvergence Engineering, Jeonbuk National University, Baekjedaero 567, Jeonju, Jeonbuk, 54896, Republic of Korea
| | - Yujin Lee
- Department of Bionanotechnology and Bioconvergence Engineering, Jeonbuk National University, Baekjedaero 567, Jeonju, Jeonbuk, 54896, Republic of Korea
| | - Dongwon Lee
- Department of Bionanotechnology and Bioconvergence Engineering, Jeonbuk National University, Baekjedaero 567, Jeonju, Jeonbuk, 54896, Republic of Korea; Department of Polymer⋅Nano Science and Technology, Jeonbuk National University, Baekjedaero 567, Jeonju, Jeonbuk, 54896, Republic of Korea.
| |
Collapse
|
2
|
Wang R, Chen H, Yan W, Zheng M, Zhang T, Zhang Y. Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships. Eur J Med Chem 2020; 190:112109. [PMID: 32032851 DOI: 10.1016/j.ejmech.2020.112109] [Citation(s) in RCA: 97] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2020] [Revised: 01/29/2020] [Accepted: 01/29/2020] [Indexed: 12/11/2022]
Abstract
Cancer is one of the most fatal threatens to human health throughout the world. The major challenges in the control and eradication of cancers are the continuous emergency of drug-resistant cancer and the low specificity of anticancer agents, creating an urgent need to develop novel anticancer agents. Organometallic compounds especially ferrocene derivatives possess remarkable structural and mechanistic diversity, inherent stability towards air, heat and light, low toxicity, low cost, reversible redox, ligand exchange, and catalytic properties, making them promising drug candidates for cancer therapy. Ferrocifen, a ferrocene-phenol hybrid, has demonstrated promising anticancer properties on drug-resistant cancers. Currently, Ferrocifen is in pre-clinical trial against cancers. Obviously, ferrocene moiety is a useful template for the development of novel anticancer agents. This review will provide an overview of ferrocene-containing hybrids with potential application in the treatment of cancers covering articles published between 2010 and 2020. The mechanisms of action, the critical aspects of design and structure-activity relationships are also discussed.
Collapse
Affiliation(s)
- Ruo Wang
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China.
| | - Huahong Chen
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Weitao Yan
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Mingwen Zheng
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Tesen Zhang
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| | - Yaohuan Zhang
- College of Chemistry, Fuzhou University, Fuzhou, Fujian, 350116, China
| |
Collapse
|
3
|
Wang Y, Zhao B, Wang L, Bu W, Liu S, Sun B. Nanoparticles based on retinoic acid caped with ferrocenium: a novel synthesized targetable nanoparticle both with anti-cancer effect and drug loading capacity. RSC Adv 2019; 9:16208-16214. [PMID: 35521379 PMCID: PMC9064344 DOI: 10.1039/c9ra02472g] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2019] [Accepted: 04/30/2019] [Indexed: 11/21/2022] Open
Abstract
To date, there is an urgent need for cancer treatment to improve in many ways in order to successfully cure all cancers. Retinoic acid (RA) is a promising anti-cancer drug through influencing cancer stem cells (CSCs). Taxol is a chemotherapy drug for many cancers. To increase the anti-cancer effects of RA and taxol, we created a novel RA nanoparticle, FCRAN, which has the ability of carrying a second anti-cancer drug, taxol, using nanotechnological methods. The results of this study demonstrated that this RA nanoparticle was water-soluble and retained the same effects as RA on cancer cells, such as inhibiting the proliferation of CSCs, inducing the differentiation of CSCs, and enhancing the sensitivity of CSCs to chemotherapeutic drugs. In addition, this RA nanoparticle can be used to carry a second anticancer drug, taxol, to become FCRAN/T and synergistically enhance the anti-cancer effects of both drugs in vivo. Interestingly, the FCRAN/T is a targetable anti-cancer nanoparticle in the presence of higher levels of glutathione (GSH) in cancer cells. Our results demonstrate that our novel synthesized nanoparticles not only retain the RA functions, but can also carry a second anticancer drug to play a synergistic anticancer role with good water solubility, in particular FCRAN/T can target cancer cells. Therefore, our novel synthesized targetable anti-cancer nanoparticles have a better application prospect than that of RA or taxol alone. A retinoic acid nanoparticle with the ability of carrying a second anti-cancer drug, taxol, was developed. The anti-cancer nanoparticles were shown to have a better application prospect than that of RA or taxol alone.![]()
Collapse
Affiliation(s)
- Yibo Wang
- Jilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Jilin University Changchun 130041 People's Republic of China
| | - Bin Zhao
- Jilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Jilin University Changchun 130041 People's Republic of China.,Department of Periodontosis, School and Hospital of Stomatology, Jilin University Changchun 130041 People's Republic of China
| | - Lu Wang
- Jilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Jilin University Changchun 130041 People's Republic of China
| | - Wenhuan Bu
- Jilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Jilin University Changchun 130041 People's Republic of China
| | - Shuwei Liu
- State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University Changchun 130012 People's Republic of China
| | - Bin Sun
- Department of Oral and Maxilloficial Surgery, School and Hospital of Stomatology, Jilin University Changchun 130041 People's Republic of China .,Jilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Jilin University Changchun 130041 People's Republic of China
| |
Collapse
|